CLINICAL TRIALS

Lymphoma (Non-Hodgkin) Clinical Trials in New Hampshire

10+ recruiting Lymphoma (Non-Hodgkin) trials in New Hampshire, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

ACTIVE NOT RECRUITINGPhase 2

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal ant

NCT01856192 · Concord
ACTIVE NOT RECRUITINGPhase 1

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain prelimina

NCT02503423 · Lebanon
ACTIVE NOT RECRUITINGPhase 3

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

NCT03844048 · Lebanon
ACTIVE NOT RECRUITINGPhase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it fir

NCT02465060 · Concord
RECRUITINGPhase 3

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europ

NCT04685616 · Stanford
ACTIVE NOT RECRUITINGPhase 3

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.

NCT03737981 · Concord
ACTIVE NOT RECRUITINGPhase 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost al

NCT06191744 · Fresno
RECRUITINGPhase 1

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B

NCT05685173 · Duarte
ACTIVE NOT RECRUITINGPhase 2

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

NCT02227251 · Tucson
ACTIVE NOT RECRUITINGPhase 3

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of t

NCT03701282 · Concord

RECOMMENDED RESOURCES FOR LYMPHOMA (NON-HODGKIN)

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
💼

eHealth Insurance

Licensed Agents

Shop ACA health plans from top insurers. Licensed agents help you find coverage that works with clinical trial participation — at no cost to you.

Compare Plans Free →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Lymphoma (Non-Hodgkin) clinical trials in New Hampshire?

Yes. Clinicals AI lists 10+ recruiting Lymphoma (Non-Hodgkin) trials in New Hampshire sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Lymphoma (Non-Hodgkin) trial in New Hampshire?

Eligibility varies by study. Most trials require a confirmed Lymphoma (Non-Hodgkin) diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Lymphoma (Non-Hodgkin) clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.